Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CT-95 |
| Synonyms | |
| Therapy Description |
CT-95 is a bispecific antibody targeting MSLN and CD3, which potentially induces antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 2139). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CT-95 | CT95|CT 95 | CD3 Antibody 119 MSLN Antibody 13 | CT-95 is a bispecific antibody targeting MSLN and CD3, which potentially induces antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 2139). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06756035 | Phase I | CT-95 | CT-95 in Advanced Cancers Associated with Mesothelin Expression | Recruiting | USA | 0 |